Comprehensive SWOT analysis reveals Gilead Sciences Inc's strategic positioning in the pharmaceutical ... Gilead Sciences Inc ...

Despite a robust HIV portfolio and growing oncology sales, Gilead struggles to diversify revenue streams significantly. Learn ...

This analysis delves into the latest insights on Gilead Sciences. The consensus rating ... with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset ...

Gilead Sciences ( GILD) increased its growth forecast for the year on strong third quarter results, marking a shift away from ...

Gilead Sciences posted robust revenue and EPS growth, exceeding expectations, and management raised full-year guidance.

Gilead Sciences Inc (NASDAQ:GILD) stock is trading higher on Thursday after the company reported better-than-expected ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Presentation Operator Good afternoon, everyone, and welcome to Gilead's Third Quarter 2024 Earnings Conference Call. My name ...

Biotech company gets a boost from treatments for HIV and COVID-19 Gilead Sciences Inc.'s stock rose ... The company's liver-disease portfolio sales rose 4% to $733 million, driven by higher ...

The consensus rating for Gilead Sciences is Neutral, based on 16 analyst ratings. With an average one-year price target of $84.25, there's a potential 6.22% downside.